| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04481c68d907208b086a245a70cf0708 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C255-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C255-23 |
| filingDate |
2000-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed4278b1716bea0347c9275816c328bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a83ab3b6d0ac56b6601c6f38e034be85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2f0237d04a945cbf9d4b8a18b791967 |
| publicationDate |
2001-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1124795-A1 |
| titleOfInvention |
Inhibitors of the egf-receptor tyrosine kinase and their use |
| abstract |
Novel compounds and pharmaceutical compositions useful as EGFR tyrosine kinase inhibitors. Methods of the invention include administration of the EGFR TK inhibitors to treat diseases characterized by enhanced expression of EGF, including cancers, particularly breast cancer. Additionally, a homology model representing the structure of EGFR kinase domain is provided, which model is useful for the rationally design and screening of compounds predicted to bind favorably to EGFR and to inhibit EGFR TK. |
| priorityDate |
1999-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |